Catalyst Pharmaceuticals Q2 2024 Adj. EPS $0.56 Beats $0.26 Estimate, Sales $122.710M Beat $111.866M Estimate
Portfolio Pulse from Benzinga Newsdesk
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported Q2 2024 adjusted EPS of $0.56, significantly beating the estimate of $0.26. Sales also surpassed expectations, reaching $122.710 million against the $111.866 million estimate. Both EPS and sales showed notable year-over-year growth.
August 07, 2024 | 8:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Catalyst Pharmaceuticals reported Q2 2024 adjusted EPS of $0.56, beating the $0.26 estimate by 115.38%. Sales of $122.710 million also exceeded the $111.866 million estimate, showing strong year-over-year growth.
The significant beat on both EPS and sales estimates, along with strong year-over-year growth, is likely to positively impact CPRX's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100